International Journal of Occupational and Environmental Health Features Discovery of Asbestos-Related Pain Origin from Scientists at the Karmanos Cancer Institute in Detroit

... of the ribs. "This action of the pleural plaque against the covering of the bone and the bone ... options to manage the pain caused by pleural plaque beyond the narcotics often prescribed for ... to show the progression of the patient's pleural plaque over a three year period, from 2005 - 2008. The ...

VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease

... targets the inflammation in atherosclerotic plaque that is thought to trigger major adverse cardiac ... lowering of hsCRP, and the potential for plaque stabilization as demonstrated by reduction in carotid plaque inflammation and non-calcified ...

vProtect(TM) Luminal Shield Stabilizes Vulnerable Plaque

... in Vessel Treated Proactively for Vulnerable plaque DOYLESTOWN, Pa., June 1 /PRNewswire/ -- ... plaque, a follow-up exam revealed reduced plaque burden and reduced stenosis in the target vessel. ... Medical, which plans to pursue a vulnerable plaque indication in the future. The patient, a ...

Video: ev3 Inc. Announces First Patient Enrollments in DEFINITIVE LE Post-Market Study

... Largest Study to Date Will Evaluate SilverHawk plaque Excision System for Treatment of Lower Extremity ... effectiveness of stand-alone SilverHawk(R) plaque Excision therapy for endovascular treatment of ... ) "The SilverHawk plaque Excision System offers patients an effective and ...

Galderma Announces Interim Data Relating to Sequential Treatment Regimen of Clobex(R) Spray Followed by Vectical(TM) Ointment in Managing Plaque Psoriasis

... findings from a study of sequential treatment of plaque psoriasis using Clobex (R) (clobetasol ... Ointment are indicated for the treatment of plaque psoriasis, this study was conducted to confirm ... phase of the study to treat moderate to severe plaque psoriasis. For subjects sufficiently clear at ...

CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients

... aged 8 years and over and adolescents with severe plaque psoriasis. If approved by the ... Union for the treatment of moderate-to-severe plaque psoriasis in adults, as well as for ankylosing ... experienced a significant improvement of their plaque psoriasis compared to those treated with placebo. ...

VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease

... of action to improvement in atherosclerotic plaque and ultimately cardiovascular outcomes." The ... reduction in macrophage inflammatory cells in plaque tissue, but met key secondary endpoints including ... CEA. CEA is a surgical procedure to remove plaque from the carotid artery to increase blood flow to ...

BioSpecifics Technologies Corp. Announces Initiation of Phase IIb Trial for Peyronie's Disease

... Modeling refers to massaging of the plaque after the second injection of a treatment series ... difficult or impossible in advanced cases. The plaque is not elastic and it does not stretch during ... without medical intervention. The most common plaque forms on the top of the penis causing the penis ...

Volcano's VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKline's Novel Investigational Compound, Darapladib

... changes in atherosclerotic plaque that occurred over time. In IBIS-2, VH(R) IVUS ... that creates colorized tissue maps of plaque composition in real-time. Despite remarkable ... the effects of investigational compounds on plaque composition. We believe that IVUS can be an ...

Phase II Data on Lilly's Antibody Show It Affects Amyloid Beta, a Protein Believed To Be Associated with Alzheimer's Disease

... with this disorder have an excess of amyloid beta plaque in the brain, particularly in the regions ... decreasing the total amount of amyloid plaque and other forms of the amyloid beta protein in ... tracer to assess levels of amyloid beta plaque in the brain. The interim analysis showed that ...

Diverse Approaches to Alzheimer's Therapies Continue to Show Progress at ICAD

... as IMPY) that measures the amount of amyloid plaque present in the brain. Measures of symptom ... the blood correlated with the amount of amyloid plaque in the brains based on IMPY scans ... that some of the beta amyloid protein present in plaque moves to blood after treatment with ...

VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial

... endarterectomy (CEA) study. The excised carotid plaque tissue will be analyzed to determine VIA-2291's ... attack and stroke. "Analyzing the carotid plaque collected in the CEA trial is a novel approach to ... of VIA-2291's effect on inflammation by analyzing plaque removed from the carotid arteries of patients ...

Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission

... psoriatic arthritis, Crohn's disease and plaque psoriasis, the safety profile for adult patients ... In the placebo-controlled clinical trials in plaque psoriasis, the incidence of arthralgia was ... of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic ...

First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System

... revealed the presence of a lipid core containing plaque not detectable by conventional diagnostic measures. This fatty plaque was located near a narrowing that required ... longer stent covered the lipid core containing plaque and avoided placing the end of a shorter stent in ...

VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial

... of the coronary vessels to evaluate the impact on plaque characteristics in a subset of patients. Patients ... VIA-2291's effect on inflammation by analyzing plaque removed from the carotid arteries in patients ... in this study include reduction in carotid plaque inflammation following dosing with VIA- 2291 as ...

PharmAthene's Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimer's Disease

... that rBChE is effective not only in inhibiting plaque formation, but also in potentially attenuating ... formation of amyloid fibrils, precursors to plaque formation in the brain. These data were ... recent studies have also demonstrated that this plaque inhibitory activity is still active when peptide ...

VIA Pharmaceuticals Completes Enrollment In Phase 2 Carotid Endarterectomy (CEA) Trial

... of VIA-2291's effect on inflammation by analyzing plaque removed from the carotid arteries of patients ... or placebo. CEA is a surgical procedure to remove plaque from the carotid artery to increase blood flow to ... vascular inflammation, as measured in the carotid plaque tissue," said Rebecca A. Taub, M.D., senior vice ...

REMICADE-Treated Patients Experienced Rapid and Substantial Improvement in Psoriasis in Critical Regions of Body

... trials showed patients with moderate to severe plaque psoriasis receiving REMICADE(R) (infliximab) ... (5 mg/kg) for the treatment of chronic severe plaque psoriasis. Following an initial three infusion ... in 378 adult patients with chronic, stable plaque psoriasis involving at least 10 percent body ...

Ustekinumab (CNTO 1275) Phase 3 Data Show Long-Term Improvement Of Chronic Plaque Psoriasis

... in the treatment of moderate to severe plaque psoriasis through one year. According to findings ... "These findings show that ustekinumab may control plaque psoriasis with as few as four injections a year," ... in the treatment of 766 patients with chronic plaque psoriasis. Patients were randomized to receive ...

Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis

... adult patients with moderate to severe chronic plaque psoriasis, an autoimmune disease characterized by ... of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy ... in many psoriasis patients." HUMIRA for plaque Psoriasis The approval of HUMIRA is based on ...

Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis

... of adult patients with chronic moderate to severe plaque psoriasis. Centocor has submitted a Biologics ... biologic in the treatment of moderate to severe plaque psoriasis," said Jerome A. Boscia, M.D., senior ... Inc. for the treatment of moderate to severe plaque psoriasis, and is being investigated as an ...

Prescient Medical, Inc. Acquires New Technology to Detect Inflammation in Coronary Blood Vessels

... and quantify the chemical composition of arterial plaque and assess its vulnerability to rupture. Each ... attack caused by the sudden rupture of soft plaque hidden inside the artery wall. This type of plaque is believed to be the major culprit in up to 80 ...

Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis

... of patients with moderate to severe plaque psoriasis receiving two doses of ustekinumab ... Inc. for the treatment of moderate to severe plaque psoriasis. These data, presented at the 21st ... 2) trial involved 1,230 patients with chronic plaque psoriasis. Patients were randomized to ...

Spherix Announces Positive Phase 2 Study Results

... mice were composed of increased collagen, indicative of a more stable plaque phenotype. The results suggest that, in addition to minimizing the extent ... consumption, a diet enriched in tagatose may favor a more stable plaque phenotype less likely to cause stroke or myocardial infarction. ...

Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for Psoriasis

... applied twice daily, for the treatment of chronic, mild-to-moderate plaque psoriasis in adults. The trial is being conducted in three centers in ... GPx mimetic SYI-2074 is being developed for treatment of mild to moderate plaque psoriasis, an inflammatory disease highly correlated with a molecular ...

VIA Pharmaceuticals Completes Patient Visits in Phase 2 Acute Coronary Syndrome (ACS) Trial

... well as medical imaging of the coronary vessels to evaluate the impact on plaque characteristics in a subset of patients. Patients in the study are treated ... measurement of biomarkers, medical imaging and atherosclerotic plaque bioassays; -- the results of our clinical trials, including without ...

Study Reveals Novel LCD Solution Provides Significant Benefits Versus Calcipotriol In Treatment Of Moderate Psoriasis

... versus calcipotriol cream (Dovonex(R)) in treatment of moderate plaque psoriasis. Specifically, results of an interim analysis reveal the LCD ... LCD against calcipotriol cream in treatment of 60 patients with moderate plaque psoriasis. The findings, representing interim results for 48 patients, ...

Interleukin Genetics Launches Enhanced Heart Health Genetic Test Report Format

... arteries. These arteries supply your heart muscle with oxygen-rich blood. plaque is made up of fat, cholesterol, and other substances found in the blood. When plaque builds up in the arteries, the condition is called atherosclerosis. ...

Patient Receives vProtect(TM) Luminal Shield in First-Ever Vulnerable Plaque Clinical Trial

... NBC's Meet the Press, is thought to have been the result of a vulnerable plaque rupture. The SECRITT investigators plan to place the self-expanding ... stenting. "Now is the time to take a new approach, to try and prevent the plaque rupture and prevent the acute event, rather than try to repair the damage ...

Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascular Disease

... impact the Company's plans to test a topical formulation of SYI-2074 in plaque psoriasis. Synvista expects to begin enrollment of patients with mild-to-moderate plaque psoriasis in a Phase 2 trial in the third quarter of 2008, as originally ...

Update on Progression of Phosphagenics and Nestle Nutrition's Phospha E(R) Trial

... of diabetes, coronary heart disease and other diseases associated with plaque build up in artery walls. The companies have agreed on the principal ... to have statistically significant reductions in key parameters such as plaque formation, aortic vascular dysfunction, cholesterol, triglycerides and ...

Zetia Does Not Reduce Carotid Plaque Size When Added to Zocor

... the researchers found that "the average thickness of the carotid artery plaque increased by 0.0111 of a millimeter in patients taking Vytorin, compared ... said that "one should not confuse the very, very small increase in carotid plaque dimension with a risk of cardiovascular events, as this event data has not ...

Cleveland Clinic to Lead First Head-to-Head Comparison of the Two Most Potent Statins

... ultrasound (IVUS), a technique that directly measures the amount of plaque in the coronary arteries. The SATURN study (Study of Coronary Atheroma ... lower LDL and raise HDL can promote regression (reduction in the amount of plaque in the coronary arteries). About Cleveland Clinic Cleveland Clinic, ...

Nestle Nutrition and Phosphagenics to Commence Phospha E(R) Phase 2 Clinical Trial

... of diabetes, coronary heart disease and other diseases associated with plaque build up in artery walls, such as stroke. The American Heart Association ... to have statistically significant reductions in key parameters such as plaque formation, aortic vascular dysfunction, cholesterol, triglycerides and ...

Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis

... with renal artery stenosis (RAS), a condition characterized by fatty plaque buildup in the kidney arteries that can lead to high blood pressure. The ... Inc. in Amarillo, Texas. In renal artery stenosis, a buildup of fatty plaque causes narrowing of the renal arteries that lead to the kidneys, organs ...

Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation

... cardiovascular events, such as heart attack and stroke, occur when plaque or fatty deposits rupture and trigger the formation of blood clots inside ... deletion of CD36 protects mice from atherosclerosis, the accumulation of plaque in blood vessels. In addition to Drs. Febbraio, Hazen, Podrez and ...

New One-Year Data from REMICADE(R) SONIC Trial Show Sustained Efficacy Compared with Azathioprine in Treatment of Crohn's Disease

... the progression of structural damage and improving physical function in patients with PsA. Treatment of adult patients with chronic severe plaque PsO who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. REMICADE is unique ...

CRESTOR(R) Reduced CV Risk in Patients Achieving Low LDL and hsCRP Targets in New JUPITER Analysis

... that CRESTOR significantly lowered LDL-C, had a significant effect on raising HDL-C and slowed the progression of atherosclerosis, the build-up of plaque in the arteries. CRESTOR has now received regulatory approval in over 90 countries. More than 13 million patients have been prescribed CRESTOR ...

CRESTOR(R) Reduced Risk of Blood Clots in the Veins

... that CRESTOR significantly lowered LDL-C, had a significant effect on raising HDL-C and slowed the progression of atherosclerosis, the build-up of plaque in the arteries. CRESTOR has now received regulatory approval in over 90 countries. More than 13 million patients have been prescribed CRESTOR ...

The Lancet Publishes Two-Year Results of Abbott's Fully Bioabsorbable Drug Eluting Stent

... previously stented area, and the drug methergin used in seven patients showing vasoconstriction in the previously stented area. Reduction in plaque area in treated arteries, corresponding to an increase in blood flow between six months and two years, as confirmed by intravascular ultrasound ...